Serum testing of genetically modified soybeans with special emphasis on potential allergenicity of the heterologous protein CP4 EPSPS

Michael Hoff, Dae Yeul Son, Michaela Gubesch, Kangmo Ahn, Sang II Lee, Stefan Vieths, Richard E. Goodman, Barbara K. Ballmer-Weber, Gary A. Bannon

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Roundup Ready soy contains the CP4-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS) protein. Serum IgE from two distinct populations of soy-allergic patients were recruited to determine their IgE-binding specificity. One population consisted of 10 adult patients from Europe, whose primary diagnosis was soy food allergy with some also having mite allergy. In addition, 6 primarily mite-allergic, 6 food-allergic (celery, carrot, milk, shrimp, walnut, and apple), and 5 non-allergic patients were tested. Another population consisted of 13 children from Korea, whose primary diagnosis was atopic dermatitis and secondarily soy and egg sensitization. In addition, 11 non-allergic patients were tested. Each patient population was extensively characterized with respect to clinical symptoms, specific IgE (CAP) scores, and total IgE. Immunoblots and ELISA assays were developed using serum IgE from these patients and soy extracts, CP4 EPSPS, rice extract, ovalbumin, rabisco, purified major peanut allergen Ara h 2, the putative soy allergen Gly m Bd 30k and mite allergen Der f 2 proteins as the intended targets. Immunoblot results indicated that soy-allergic patients bound soy extracts but did not specifically bind rabisco or CP4 EPSPS. ELISA results were in general agreement with the immunoblot results except that rubisco bound significant quantities of serum IgE from some patients. These results indicate that the CP4 EPSPS protein does not bind significant quantities of IgE from two geographically distinct sensitive populations and there is no evidence for an increased allergenic potential of this biotech protein.

Original languageEnglish (US)
Pages (from-to)946-955
Number of pages10
JournalMolecular Nutrition and Food Research
Volume51
Issue number8
DOIs
StatePublished - Aug 1 2007

Fingerprint

allergenicity
Soybeans
Immunoglobulin E
Phosphates
phosphates
soybeans
Serum
Mites
Proteins
proteins
allergens
testing
mites
glyphosate
Population
extracts
Enzyme-Linked Immunosorbent Assay
Apium graveolens
enzyme-linked immunosorbent assay
Juglans

Keywords

  • Atopic
  • CP4 EPSPS
  • Food allergy
  • IgE
  • Soy allergy

ASJC Scopus subject areas

  • Biotechnology
  • Food Science

Cite this

Serum testing of genetically modified soybeans with special emphasis on potential allergenicity of the heterologous protein CP4 EPSPS. / Hoff, Michael; Son, Dae Yeul; Gubesch, Michaela; Ahn, Kangmo; Lee, Sang II; Vieths, Stefan; Goodman, Richard E.; Ballmer-Weber, Barbara K.; Bannon, Gary A.

In: Molecular Nutrition and Food Research, Vol. 51, No. 8, 01.08.2007, p. 946-955.

Research output: Contribution to journalArticle

Hoff, Michael ; Son, Dae Yeul ; Gubesch, Michaela ; Ahn, Kangmo ; Lee, Sang II ; Vieths, Stefan ; Goodman, Richard E. ; Ballmer-Weber, Barbara K. ; Bannon, Gary A. / Serum testing of genetically modified soybeans with special emphasis on potential allergenicity of the heterologous protein CP4 EPSPS. In: Molecular Nutrition and Food Research. 2007 ; Vol. 51, No. 8. pp. 946-955.
@article{5020870266994c218d8b96dc9398a4a4,
title = "Serum testing of genetically modified soybeans with special emphasis on potential allergenicity of the heterologous protein CP4 EPSPS",
abstract = "Roundup Ready soy contains the CP4-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS) protein. Serum IgE from two distinct populations of soy-allergic patients were recruited to determine their IgE-binding specificity. One population consisted of 10 adult patients from Europe, whose primary diagnosis was soy food allergy with some also having mite allergy. In addition, 6 primarily mite-allergic, 6 food-allergic (celery, carrot, milk, shrimp, walnut, and apple), and 5 non-allergic patients were tested. Another population consisted of 13 children from Korea, whose primary diagnosis was atopic dermatitis and secondarily soy and egg sensitization. In addition, 11 non-allergic patients were tested. Each patient population was extensively characterized with respect to clinical symptoms, specific IgE (CAP) scores, and total IgE. Immunoblots and ELISA assays were developed using serum IgE from these patients and soy extracts, CP4 EPSPS, rice extract, ovalbumin, rabisco, purified major peanut allergen Ara h 2, the putative soy allergen Gly m Bd 30k and mite allergen Der f 2 proteins as the intended targets. Immunoblot results indicated that soy-allergic patients bound soy extracts but did not specifically bind rabisco or CP4 EPSPS. ELISA results were in general agreement with the immunoblot results except that rubisco bound significant quantities of serum IgE from some patients. These results indicate that the CP4 EPSPS protein does not bind significant quantities of IgE from two geographically distinct sensitive populations and there is no evidence for an increased allergenic potential of this biotech protein.",
keywords = "Atopic, CP4 EPSPS, Food allergy, IgE, Soy allergy",
author = "Michael Hoff and Son, {Dae Yeul} and Michaela Gubesch and Kangmo Ahn and Lee, {Sang II} and Stefan Vieths and Goodman, {Richard E.} and Ballmer-Weber, {Barbara K.} and Bannon, {Gary A.}",
year = "2007",
month = "8",
day = "1",
doi = "10.1002/mnfr.200600285",
language = "English (US)",
volume = "51",
pages = "946--955",
journal = "Molecular Nutrition and Food Research",
issn = "1613-4125",
publisher = "Wiley-VCH Verlag",
number = "8",

}

TY - JOUR

T1 - Serum testing of genetically modified soybeans with special emphasis on potential allergenicity of the heterologous protein CP4 EPSPS

AU - Hoff, Michael

AU - Son, Dae Yeul

AU - Gubesch, Michaela

AU - Ahn, Kangmo

AU - Lee, Sang II

AU - Vieths, Stefan

AU - Goodman, Richard E.

AU - Ballmer-Weber, Barbara K.

AU - Bannon, Gary A.

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Roundup Ready soy contains the CP4-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS) protein. Serum IgE from two distinct populations of soy-allergic patients were recruited to determine their IgE-binding specificity. One population consisted of 10 adult patients from Europe, whose primary diagnosis was soy food allergy with some also having mite allergy. In addition, 6 primarily mite-allergic, 6 food-allergic (celery, carrot, milk, shrimp, walnut, and apple), and 5 non-allergic patients were tested. Another population consisted of 13 children from Korea, whose primary diagnosis was atopic dermatitis and secondarily soy and egg sensitization. In addition, 11 non-allergic patients were tested. Each patient population was extensively characterized with respect to clinical symptoms, specific IgE (CAP) scores, and total IgE. Immunoblots and ELISA assays were developed using serum IgE from these patients and soy extracts, CP4 EPSPS, rice extract, ovalbumin, rabisco, purified major peanut allergen Ara h 2, the putative soy allergen Gly m Bd 30k and mite allergen Der f 2 proteins as the intended targets. Immunoblot results indicated that soy-allergic patients bound soy extracts but did not specifically bind rabisco or CP4 EPSPS. ELISA results were in general agreement with the immunoblot results except that rubisco bound significant quantities of serum IgE from some patients. These results indicate that the CP4 EPSPS protein does not bind significant quantities of IgE from two geographically distinct sensitive populations and there is no evidence for an increased allergenic potential of this biotech protein.

AB - Roundup Ready soy contains the CP4-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS) protein. Serum IgE from two distinct populations of soy-allergic patients were recruited to determine their IgE-binding specificity. One population consisted of 10 adult patients from Europe, whose primary diagnosis was soy food allergy with some also having mite allergy. In addition, 6 primarily mite-allergic, 6 food-allergic (celery, carrot, milk, shrimp, walnut, and apple), and 5 non-allergic patients were tested. Another population consisted of 13 children from Korea, whose primary diagnosis was atopic dermatitis and secondarily soy and egg sensitization. In addition, 11 non-allergic patients were tested. Each patient population was extensively characterized with respect to clinical symptoms, specific IgE (CAP) scores, and total IgE. Immunoblots and ELISA assays were developed using serum IgE from these patients and soy extracts, CP4 EPSPS, rice extract, ovalbumin, rabisco, purified major peanut allergen Ara h 2, the putative soy allergen Gly m Bd 30k and mite allergen Der f 2 proteins as the intended targets. Immunoblot results indicated that soy-allergic patients bound soy extracts but did not specifically bind rabisco or CP4 EPSPS. ELISA results were in general agreement with the immunoblot results except that rubisco bound significant quantities of serum IgE from some patients. These results indicate that the CP4 EPSPS protein does not bind significant quantities of IgE from two geographically distinct sensitive populations and there is no evidence for an increased allergenic potential of this biotech protein.

KW - Atopic

KW - CP4 EPSPS

KW - Food allergy

KW - IgE

KW - Soy allergy

UR - http://www.scopus.com/inward/record.url?scp=34548081797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548081797&partnerID=8YFLogxK

U2 - 10.1002/mnfr.200600285

DO - 10.1002/mnfr.200600285

M3 - Article

C2 - 17639514

AN - SCOPUS:34548081797

VL - 51

SP - 946

EP - 955

JO - Molecular Nutrition and Food Research

JF - Molecular Nutrition and Food Research

SN - 1613-4125

IS - 8

ER -